Trials / Completed

CompletedNCT02728206

Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation

A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir Fixed Dose Combination Administered for Four Weeks in Patients Infected With Chronic HCV in the Peri-Operative Liver Transplantation Setting

Status: Completed
Phase: Phase 2
Study type: Interventional
Enrollment: 9 (actual)

Sponsor: Gilead Sciences · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) in hepatitis C virus (HCV)-infected adults who are undergoing liver transplantation.

Conditions

Hepatitis C Virus Infection

Interventions

Type	Name	Description
DRUG	SOF/VEL	400/100 mg FDC tablet administered orally once daily

Timeline

Start date: 2016-06-12
Primary completion: 2018-01-16
Completion: 2018-01-16
First posted: 2016-04-05
Last updated: 2019-02-06
Results posted: 2019-02-06

Locations

1 site across 1 country: New Zealand

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT02728206. Inclusion in this directory is not an endorsement.